Results 41 to 50 of about 15,382 (226)
Paroxysmal Nocturnal Hemoglobinuria in Myelofibrosis [PDF]
Abstract Ten consecutive patients with myelofibrosis were examined for the following signs of PNH: Ham’s test, the sucrose hemolysis test, low red cell acetylcholinesterase (ACHE) activity and intravascular hemolysis. Two of the patients displayed all these signs and also had clinical symptoms of PNH.
N E, Hansen, S A, Killmann
openaire +2 more sources
Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome are diseases of excess activation of the alternative pathway of complement that are treated with eculizumab, a humanized monoclonal antibody against the terminal complement ...
Xuan Yuan +8 more
doaj +1 more source
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, hematologic disease characterized by complement-mediated hemolysis, thrombosis, and various degrees of bone marrow dysfunction.
R. Wong
semanticscholar +1 more source
Paroxysmal nocturnal hemoglobinuria in systemic lupus erythematosus: a case report
Introduction Paroxysmal nocturnal hemoglobinuria is an acquired disorder of hemopoiesis and is characterized by recurrent episodes of intravascular hemolysis due to an increased sensitivity to complement-mediated hemolysis.
Nakamura Norio +11 more
doaj +1 more source
Background Clones of glycosylphosphatidylinositol-anchor protein-deficient cells are characteristic in paroxysmal nocturnal hemoglobinuria and are present in about 40–50% of patients with severe aplastic anemia.
Phillip Scheinberg +3 more
doaj +1 more source
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic hematologic disorder associated with inappropriate terminal complement activity on blood cells that can result in intravascular hemolysis (IVH), thromboembolic events (TEs), and organ damage ...
A. Kulasekararaj +4 more
semanticscholar +1 more source
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
BACKGROUND Persistent hemolytic anemia and a lack of oral treatments are challenges for patients with paroxysmal nocturnal hemoglobinuria who have received anti-C5 therapy or have not received complement inhibitors.
R. Peffault de Latour +52 more
semanticscholar +1 more source
Objective: To discuss the implementation of technical advances in laboratory diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria for validation of high-sensitivity flow cytometry protocols. Methods: A retrospective study based on analysis of
Rodolfo Patussi Correia +11 more
doaj +1 more source
Crovalimab is a novel C5 complement inhibitor that enables rapid and sustained C5 inhibition with subcutaneous, low‐volume self‐administration every 4 weeks.
Alexander Röth +27 more
semanticscholar +1 more source
Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience
Background Pregnancy in women with paroxysmal nocturnal hemoglobinuria is rare, with few reports on maternal and fetal mortality rates.Design and Methods A specific questionnaire designed to solicit data on pregnancies in women with paroxysmal nocturnal ...
Sophie de Guibert +14 more
doaj +1 more source

